India is stepping into the billion-dollar weight-loss drug war! With Wegovy and Mounjaro already here, Biocon is quietly ...

Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines ...

Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving ...

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars Bengaluru, Karnataka, India, July 7, 2025  Biocon Biologics Ltd (BBL), a fully integrated global biosimilars ...